Malaria Information and Prophylaxis, by Country [N]

The information presented in this table is consistent 1 with the information in the CDC Health Information for International Travel (the “Yellow Book”).

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Malaria Information and Prophylaxis by Country
Country Areas with Malaria Drug Resistance2 Malaria Species3 Recommended Chemoprophylaxis4 Key Information Needed and Helpful Links to Assess Need for Prophylaxis for Select Countries
Namibia Present in the regions of Kavango (East and West), Kunene, Ohangwena, Omusati, Oshana, Oshikoto, Otjozunjupa, and Zambezi. Rare cases in other parts of the country. No malaria in city of Windhoek. Chloroquine P. falciparum >90%,

P. malariae, P. ovale, and P. vivax rare

Kavango (East and West), Kunene, Ohangwena, Omusati, Oshana, Oshikoto, Otjozunupa, and Zambezi: Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6. Other parts of the country with rare cases: Mosquito avoidance only.
Nauru None Not Applicable Not Applicable Not Applicable
Nepal Present throughout country at altitudes < 2,000 m (6,562 ft). None in Kathmandu and on typical Himalayan treks. Chloroquine P. vivax 85%,

P. falciparum 15%

Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6
Netherlands None Not Applicable Not Applicable Not Applicable
Netherlands Antilles (Bonaire, Curaçao, Saba, St. Eustasius, and St. Martin) None Not Applicable Not Applicable Not Applicable
New Caledonia (France) None Not Applicable Not Applicable Not Applicable
New Zealand None Not Applicable Not Applicable Not Applicable
Nicaragua Present in Región Autónoma Atlántico Norte (RAAN) and Región Autónoma Atlántico Sur (RAAS). Rare cases in Boaco, Chinandega, Esteli, Jinotega, Leon, Matagalpa, and Nueva Segovia. No malaria in the city of Managua. None P. vivax 90%,

P. falciparum 10%

Región Autónoma Atlántico Norte (RAAN) and Región Autónoma Atlántico Sur (RAAS): Atovaquone-proguanil, chloroquine, doxycycline, mefloquine, or tafenoquine6. Other areas with malaria: Mosquito avoidance only.
Niger All Chloroquine P. falciparum 85%,

P. ovale 5-10%,

P. vivax rare

Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6
Nigeria All Chloroquine P. falciparum >85%,

P. ovale 5-10%,

P. vivax rare

Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6
Niue (New Zealand) None Not Applicable Not Applicable Not Applicable
Norfolk Island (Australia) None Not Applicable Not Applicable Not Applicable
North Korea Present in southern provinces None Presumed to be 100% P. vivax Atovaquone-proguanil, chloroquine, doxycycline, mefloquine, primaquine,6 or tafenoquine6
Northern Mariana Islands (US) Includes Saipan, Tinian, and Rota Island None Not Applicable Not Applicable Not Applicable
Norway None Not Applicable Not Applicable Not Applicable

1. Factors that affect local malaria transmission patterns can change rapidly and from year to year, such as local weather conditions, mosquito vector density, and prevalence of infection. Information in these tables is updated regularly.
2. Refers to P. falciparum malaria unless otherwise noted.
3. Estimates of malaria species are based on best available data from multiple sources.
4. Several medications are available for chemoprophylaxis. When deciding which drug to use, consider specific itinerary, length of trip, cost of drug, previous adverse reactions to antimalarials, drug allergies, and current medical history. All travelers should seek medical attention in the event of fever during or after return from travel to areas with malaria.
5. This risk estimate is based largely on cases occurring in US military personnel who travel for extended periods of time with unique itineraries that likely do not reflect the risk for the average US traveler.
6. Primaquine and tafenoquine can cause hemolytic anemia in persons with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Patients must be screened for G6PD deficiency prior to starting primaquine.

Page last reviewed: March 27, 2019